<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="116534">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01586091</url>
  </required_header>
  <id_info>
    <org_study_id>2010-022747-38</org_study_id>
    <nct_id>NCT01586091</nct_id>
  </id_info>
  <brief_title>Safety Study of Levocetirizine and Fexofenadine</brief_title>
  <acronym>LAWAF</acronym>
  <official_title>Comparison of Efficacy and Consistency of Action of Levocetirizine 5 mg Once Daily With Fexofenadine 60 mg Twice Daily in the Histamine Induced Wheal, Flare and Itch Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective:

      The comparative efficacy of levocetirizine 5 mg once daily with that of fexofenadine 60 mg
      twice daily against histamine induced wheal, flare and itch responses measured at 0
      (baseline), 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours.

      Secondary objectives:

        1. The areas under the curves (0 , 12 hours, 12 - 24 hours and 0 - 24 hours) for
           inhibition of histamine induced wheal, flare and itch responses for levocetirizine 5 mg
           once daily and fexofenadine 60 mg twice daily.

        2. The number of individuals with peak responses in each 10 percentile (Because of the
           variable absorption of fexofenadine, it is predicted that fexofenadine will have a
           variable response between individuals).

        3. The mean plasma levels of levocetirizine and fexofenadine at 0 (baseline), 0.5, 1, 2,
           3, 4, 6, 8, 10, 12 and 24 hours.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of Efficacy and Consistency of Action of Levocetirizine 5 mg once daily with Fexofenadine 60 mg twice daily in the histamine induced wheal- and flare and itch response</measure>
    <time_frame>24 hours per treatment - two visits</time_frame>
    <description>The comparative efficacy of levocetirizine 5 mg once daily with that of fexofenadine 60 mg twice daily against histamine induced wheal, flare and itch responses measured at 0 (baseline), 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>levocetirizine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>fexofenadine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levocetirizine</intervention_name>
    <description>levocetirizine 5 mg once daily</description>
    <arm_group_label>levocetirizine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fexofenadine</intervention_name>
    <description>fexofenadine 60 mg twice daily, oral</description>
    <arm_group_label>fexofenadine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eighteen (18) healthy male volunteers, including at least 6 persons of Japanese
             origin, will be recruited for this study

        Exclusion Criteria:

          -  None of the subjects will have taken oral antihistamines, antidepressants,
             antipsychotics or corticosteroids or applied topical antihistamines, corticosteroids
             or mast cell stabilizers to the skin for 2 weeks prior to testing.

          -  No subject shall perform physical exercise for 4 hours prior to the skin prick
             testing.

          -  Especially, Bronchial asthma, anaphylactic reactions in the history, use of
             beta-blockers, skin diseases in the test field are exclusion criteria.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcus Maurer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite Universitätsmedizin Berlin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Berlin Charité</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <lastchanged_date>April 24, 2012</lastchanged_date>
  <firstreceived_date>April 23, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Martin Metz</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Levocetirizine</mesh_term>
    <mesh_term>Cetirizine</mesh_term>
    <mesh_term>Fexofenadine</mesh_term>
    <mesh_term>Terfenadine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
